Patent ID: 9610260
Date: 2017-04-04
CPC Classifications: A61K,A61P,C12Q

Claim:
1. A method of treating seizures in a patient diagnosed with Dravet syndrome and exhibiting a mutation in one, some or all of the genes selected from the group consisting of SCN1A, SCN1B, SCN2A, SCN3A, SCN9A, GABRG2, GABRD and PCDH19 comprising administering to said patient an effective dose of fenfluramine or a pharmaceutically acceptable salt thereof; administering an effective dose of stiripentol or a pharmaceutically acceptable salt thereof to said patient; administering an effective dose of a valproate or a pharmaceutically acceptable salt thereof to said patient; and administering an effective dose of clobazam or a pharmaceutically acceptable salt thereof to said patient, whereby seizures are ameliorated in the patient exhibiting the mutation.